Showing results (2031-2040 of 2,087) with videos related to

Sort By:
Pageof 209
Leukemia|July 2, 2016
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemiasK Wang, M Sanchez-Martin, X Wang, et al.
Actas Urologicas Espanolas|July 9, 2008
[Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer]J M Cózar Olmo, J Carballido Rodriguez, P Luque Galvez, et al.
Journal of the American College of Cardiology|June 12, 2024
Impact of Social Determinants of Health on Predictive Models for Outcomes After Congenital Heart SurgerySarah Crook, Kacie Dragan, Joyce L Woo, et al.
British Journal of Haematology|July 7, 2018
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithmCarlos Montalbán, Antonio Díaz-López, Alejandro Martín, et al.
Journal of Dental Research|October 29, 2024
Oral Health Research in the WHO African Region between 2011 and 2022: A Scoping ReviewT F Labarca, D Ortuño, L Neira, et al.
Allergy|March 10, 2011
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paperI Baiardini, F Braido, C Bindslev-Jensen, et al.
BMJ Global Health|July 10, 2026
The science of child and adolescent mental health in Brazil: a nationwide systematic review and compendium of evidence-based resourcesLauro Estivalete Marchionatti, André Cardoso Campello, Jessica Azevedo Veronesi, et al.
Annals of the American Thoracic Society|May 29, 2025
Post-Thoracentesis Ultrasound versus Chest Radiography for the Evaluation of Effusion Evacuation and Lung Reexpansion: A Multicenter StudyAnkush Ratwani, Horiana B Grosu, Shaikh M Noor Husnain, et al.
The Journal of Headache and Pain|December 3, 2024
Resistant and refractory migraine - two different entities with different comorbidities? Results from the REFINE studyC Rosignoli, R Ornello, V Caponnetto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Pageof 209